Nanjing Vazyme Biotech Co Ltd (688105) - Net Assets
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has net assets worth CN¥3.79 Billion CNY (≈ $554.99 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.10 Billion ≈ $746.43 Million USD) and total liabilities (CN¥1.31 Billion ≈ $191.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Nanjing Vazyme Biotech Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.79 Billion |
| % of Total Assets | 74.35% |
| Annual Growth Rate | 49.64% |
| 5-Year Change | -8.14% |
| 10-Year Change | N/A |
| Growth Volatility | 188.88 |
Nanjing Vazyme Biotech Co Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See Nanjing Vazyme Biotech Co Ltd (688105) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual net assets of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. For live valuation and market cap data, see 688105 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.79 Billion ≈ $554.78 Million |
-3.86% |
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
-2.13% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
-12.64% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
+11.75% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
+209.77% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
+566.12% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
+20.44% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
+10.12% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Vazyme Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 89646491276.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥861.73 Million | 22.70% |
| Other Components | CN¥2.93 Billion | 77.30% |
| Total Equity | CN¥3.80 Billion | 100.00% |
Nanjing Vazyme Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Imperial Metals Corporation
TO:III
|
$915.09 Million |
|
Giant Manufacturing Co Ltd
TW:9921
|
$915.30 Million |
|
Lotte Tour Dev
KO:032350
|
$915.44 Million |
|
Colorlight Cloud Tech Ltd. A
SHE:301391
|
$915.56 Million |
|
KSB SE & Co. KGaA
XETRA:KSB
|
$914.23 Million |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
$914.19 Million |
|
Central Pacific Financial Corp
NYSE:CPF
|
$913.85 Million |
|
Tianjin Benefo Tejing Electric Co Ltd
SHG:600468
|
$913.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Vazyme Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,945,243,056 to 3,796,066,716, a change of -149,176,340 (-3.8%).
- Net loss of 16,970,224 reduced equity.
- Dividend payments of 77,461,461 reduced retained earnings.
- Other factors decreased equity by 54,744,655.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-16.97 Million | -0.45% |
| Dividends Paid | CN¥77.46 Million | -2.04% |
| Other Changes | CN¥-54.74 Million | -1.44% |
| Total Change | CN¥- | -3.78% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Vazyme Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 37.08x to 1.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.42 | CN¥15.72 | x |
| 2018-12-31 | CN¥0.47 | CN¥15.72 | x |
| 2019-12-31 | CN¥0.50 | CN¥15.72 | x |
| 2020-12-31 | CN¥3.75 | CN¥15.72 | x |
| 2021-12-31 | CN¥11.38 | CN¥15.72 | x |
| 2022-12-31 | CN¥11.56 | CN¥15.72 | x |
| 2023-12-31 | CN¥10.22 | CN¥15.72 | x |
| 2024-12-31 | CN¥10.90 | CN¥15.72 | x |
| 2025-12-31 | CN¥8.95 | CN¥15.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Vazyme Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.23%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.32x
- Recent ROE (-0.45%) is below the historical average (11.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 2.42% | 3.24% | 0.60x | 1.25x | CN¥-11.44 Million |
| 2018 | 0.63% | 0.61% | 0.68x | 1.51x | CN¥-15.57 Million |
| 2019 | 12.90% | 9.61% | 0.83x | 1.62x | CN¥5.79 Million |
| 2020 | 61.67% | 52.52% | 0.97x | 1.21x | CN¥688.49 Million |
| 2021 | 16.43% | 36.30% | 0.41x | 1.12x | CN¥265.56 Million |
| 2022 | 12.89% | 16.65% | 0.59x | 1.30x | CN¥133.35 Million |
| 2023 | -1.76% | -5.52% | 0.22x | 1.43x | CN¥-473.90 Million |
| 2024 | -0.46% | -1.31% | 0.27x | 1.28x | CN¥-412.62 Million |
| 2025 | -0.45% | -1.23% | 0.27x | 1.32x | CN¥-396.58 Million |
Industry Comparison
This section compares Nanjing Vazyme Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Vazyme Biotech Co Ltd (688105) | CN¥3.79 Billion | 2.42% | 0.34x | $914.92 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more